Donald E. Morel, Jr., Ph.D.

Chairman and Chief Executive Officer

William J. Federici

Vice President and Chief Financial Officer

Investor Relations Contact:

Michael A. Anderson

Vice President and Treasurer

mike.anderson@westpharma.com

UBS Global Specialty Pharmaceuticals Conference

June 3, 2009London, UK

NYSE: WST

westpharma.com

All trademarks and registered trademarks are the property of West Pharmaceutical Services, Inc., unless noted otherwise.

1

This presentation contains forward-looking statements, within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, that are based on management’s beliefs and
assumptions, current expectations, estimates and forecasts.Statements that are not
historical facts, including statements that are preceded by, followed by, or that
include, words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate”
and other words and terms of similar meaning are forward-looking statements.West’s
estimated or anticipated future results, product performance or other non-historical
facts are forward-looking and reflect our current perspective on existing trends and
information.

Many of the factors that will determine the Company’s future results are beyond the
ability of the Company to control or predict.These statements are subject to known or
unknown risks or uncertainties, and therefore, actual results could differ materially
from past results and those expressed or implied in any forward-looking statement.
You should bear this in mind as you consider forward-looking statements. A non-
exclusive list of important factors that may affect future results may be found in
West’s filings with the Securities and Exchange Commission, including our annual
report on Form 10-K and our periodic reports on Form 10-Q and Form 8-K.

You should evaluate any statement in light of these important factors.

Forward Looking Statements

2

Who We Are

•Founded in 1923

•Global Headquarters near
Philadelphia

•Market capitalization $1.2 billion

•World’s premier manufacturer
of components and systems
for injectable drug delivery

–Closure systems and prefillable
syringe components

–Components for disposable
systems

–Devices and device sub-
assemblies

–Safety and administration
systems

3

West’s Competitive Advantage

•Global manufacturing footprint

•Unmatched experience/expertise: drug - material interface

–Global regulatory and technical support

•Protected IP: Proprietary materials and technology

•Regulatory barrier to entry:US NDA and ANDA filing must
include reference to all packaging/components in contact
with the drug

1.West Drug Master File (DMF) 1546 is confidential

2.West DMF includes functionality data (multi-year studies)

3.Primary package changes require new stability/functionality
studies for new filing

•Engineering expertise in high-volume manufacturing, assembly
and vision inspection

4

Diverse, Stable Customer Base

5

Sales and Income from Continuing Operations
($ in millions)

6

Exubera is a registered trademark of Pfizer, Inc.

2008 Overview

•A challenging year

–Exubera, ESA packaging, diagnostic
component lost sales impact

–Commodity, currency market instability

–Global economic downturn

•Strong growth in core component sales

•Tech restructuring completed

•China plant construction underway

•Expansion programs on schedule/budget

7

Outlook for 2009 and Beyond

•Global pharma remains under substantial pressure

•Global growth projected at 2.5-5% (down from 5-7%)

•North America down 1-2%

•Europe 0-1%

•Emerging economies 5-7% (India, China, Brazil)

•US election and government plans for health care

•Pharmaceutical Industry changes - consolidation

•Pfizer - Wyeth

•Roche -Genentech

•AstraZeneca -Medimmune

•Lilly - Imclone

•Merck Bioventures - Insmed

•Changing order patterns

•Delivering against customer expectations

•Value (price in their world)

•Quality

•How do we best position West for future growth in a dramatically changing marketplace?

8

Drug Packaging

(How it is contained)

Primary Container Solutions

Prefillable Syringe Systems

Drug Delivery

(How it gets into the patient)

Administration Systems

Advanced Injection Systems

Development

Primary Package

Administration

Our Growth Opportunities

9

Autoimmune Disease

Vaccines

Oncology

Diabetes

Market Dynamics Support Future Growth

•Increasing number of patients
with chronic illnesses

•Many of these are treated with
biologic drugs

•Biologic drugs demand ultra-
clean delivery systems

•Point of care shift: Hospital to
specialty clinic to home

•Safe, accurate dosing needs
are pushing the market toward
integrating the container/
closure system into the delivery
system

•Generic growth

10

Total
39

Total
106

2007’s 22 Biotech Blockbusters

Enbrel (Amgen/Wyeth)

Aranesp (Amgen)

Remicade (J&J/SP)

Rituxan (Roche)

Neulasta (Amgen)

Erypo/Procrit (J&J)

Herceptin (Roche)

Epogen (Amgen)

Avastin (Roche)

Humira (Abbott)

Lantus (Sanofi-Aventis)

Avonex (Biogen Idec)

Neorecormon (Roche)

Gardasil (Merck)

Rebif (Serono)

Neupogen (Amgen)

Novorapid (Novo Nordisk)

Erbitux (Imclone/Merck KGaA/BMS)

Lucentis (Roche/Novartis/Genentech)

Synagis (MedImmune)

Humalog (Lilly)

Betaferon (Bayer/Schering AG)

Sources: IMS 2008 Global Biotech Perspective report and Company
Estimates

West participates in all of the 2007
Biotech Blockbuster drug products

Global Biotech Blockbusters(Annual Sales >$1Billion)

11

Millions of
insulin
dependents
worldwide

Compare to
246 million
diabetics
worldwide

Year

Source: Company estimate

2005-2010 17% Increase in Projected Number

For Insulin Dependent Diabetics

12

Drug Packaging

(How it is contained)

Primary Container Solutions

Prefillable Syringe Systems

Drug Delivery

(How it gets into the patient)

Administration Systems

Advanced Injection Systems

•Build market share in multi-
component systems for drug
administration

•Expand proprietary product portfolio
through innovation and strategic
technology acquisitions

•Market segmentation to generate
organic growth

•New product innovation

•Lean manufacturing

•Strategic acquisitions

•Geographic expansion

•Capacity build - Europe, Singapore,
North America

•China plastics

•India rubber site selection

Our Growth Strategy

13

West FluroTec®
Components

Seal - Stopper - Vial

Daikyo Crystal Zenith® Vials

Estimated Market Size - $1.5 billion

CAGR - 4%

Source: Company estimate for vial systems only

West Spectra™ Seals

Crystal Zenith is a registered trademark of Daikyo Seiko, Ltd.

FluroTec and Crystal Zenith technologies are licensed from Daikyo Seiko, Ltd.

Primary Drug Packaging

14

Uncoated 4432/50 V35

$50

$200

4432/50 S2 FluroTec®
Westar RS

$250

4432/50 S2 FluroTec®Westar RS B2-40 Port Bag

$300

4432/50 S2 FluroTec®Westar® RS B2-40
(1000 packs)

$465

4432/50 Sterile S2 W
(RU) Ready Pack
(1000 packs)

$2,900

RU Ready Pack System
(small volume sourcing only)

$3,500

$360

Core Strategy - Adding Incremental Value per Unit

15

West NovaPure™

•Item-specific subvisible particle specification

•Residual moisture specification for lyophilization stoppers

•Helps meet Quality by Design initiatives

•Designed to mitigate risks associated with drug packaging

16

China Plastics Facility

17

Drug Packaging

(How it is contained)

Primary Container Solutions

Prefillable Syringe Systems

Drug Delivery

(How it gets into the patient)

Administration Systems

Advanced Injection Systems

•Build market share in multi-
component systems for drug
administration

•Expand proprietary product portfolio
through innovation and strategic
technology acquisitions

•Market segmentation to generate
organic growth

•New product innovation

•Lean manufacturing

•Strategic acquisitions

•Geographic expansion

•Capacity build - Europe, Singapore,
North America

•China plastics

•India rubber site selection

Our Growth Strategy

18

Vial2Bag™

Mix2Vial®

MixJect®

NovaGuard™
Safety Needle
Device

ConfiDose®
Auto-injector

Daikyo Crystal Zenith®

Delivery Systems - Key Programs

19

Packaging & Delivery Systems for Large Molecules Key Driver

•Currently all large molecule drugs are delivered
by injection

•West components are preferred and used for
the top selling biotech therapeutics

•Used predominantly to treat chronic diseases

–Diabetes

–Cancer

–Auto-immune

•Fastest growing segment of our business

•Strong profit driver

20

Critical Stability Issues for Biotechnology Drugs

•Aggregation

–Silicone, tungsten, glue, mfg. processing

•Adsorption - vials and syringes

–Impacts potency of large molecules

•Immunogenicity/Neurogenicity

•Polysorbate 20 and 80

–Detergents used for mitigating aggregation

–Highly unpredictable

•Too much creates aggregation

•Potential for peroxide creation

21

Higher extent of aggregation in glass compared to CZ

Daikyo Crystal Zenith

Glass

Daikyo Crystal Zenith® vs. Glass
(Demonstrated employing a model antibody in solution)

22

First-in-Human Containers

Bulk Containers

Inserted Needle Syringes

•Stored frozen in
Phase 1

•Ideal cleanliness

•Low adsorption
properties

•Ideal for auto-injectors

•No tungsten, glue or
silicone

•Ease of handling

Daikyo Crystal Zenith® and Flurotec® are registered trademarks of Daikyo Seiko,
Ltd.

Total Life Cycle Containment
Daikyo Crystal Zenith®

•Polybutadiene
Flurotec® liner

•Low temperature
resistance

•Ease of handling

23

Drug Packaging

(How it is contained)

Primary Container Solutions

Prefillable Syringe Systems

Drug Delivery

(How it gets into the patient)

Administration Systems

Advanced Injection Systems

$2 billion combined markets for safety,
prefilled and autoinjectors:

•Unit growth 6-12%, varies depending
on segment

•West 2008 sales: $170 million

•2013 OP margin: 7%

Strategic Planning Goals - Systems:

•Projected 2013 sales of $550million

•Projected 2013 OP margin 20%

$1.5 billion market for components

•Unit growth 0-8% per year depending
on segment

•West 2008 sales: $800 million

•2008 OP margin: 17.5%

Strategic Planning Goals - components:

•Projected 2013 sales of $1.05 billion

•Projected 2013 OP margin 20%

Five-Year Forecasted Growth Opportunity

24

	2009	2008
Net Sales	$242.4	$270.7
Gross Margin	28.6%	30.8%
R&D	$4.3	$5.4
SG&A	$42.9	$40.1
Operating Profit (Non-GAAP) *	$21.9	$37.8
Net Income (Non-GAAP) *	$14.1	$24.9
Diluted EPS (Non-GAAP) *	$0.42	$0.72

*2009 operating profit, net income and diluted EPS excludes a ($0.01) per share impact of Tech restructuring charges and $0.05

per share of discrete tax benefits.

*2008 operating profit, net income and diluted EPS excludes a $0.03 per share net gain on the Nektar contract settlement, a ($0.02)

per share impact of Tech restructuring charges and $0.03 per share of discrete tax benefits.

First Quarter Results
($ in millions, except per share data)

25

($M)	3/31/09	12/31/08	3/31/08
Cash	$62.7	$87.2	$93.6
Accounts Receivable	$137.2	$128.6	$151.9
Days Sales Outstanding (DSO)	50.9	44.8	51.1
Inventory	$120.0	$115.7	$119.3
Days Inventory Outstanding (DIO)	44.6	40.3	40.1

Asset Management

26

($M)	3/31/09	12/31/08
Total Debt	$387.9	$386.0
Total Equity	$488.6	$487.1
Net Debt to Total Capital	40.0%	38.0%
Capital Expenditures:
YTD Spending	$17.8
Full Year Forecast / Actual	$128.7	$131.8

Capital Management

27

Maintaining Our Long-term Focus

•The fundamentals are what matter

–Superior quality and service win

–The Global Quality Initiative is critical

•Margin improvement - lean manufacturing, OEE

•Continue investment for the future

–Innovation

–Capacity and emerging markets

–IT

–Technology & product acquisitions

–People

•Financial

–Operating cash flow

–Prudent spending: discretionary SG&A and Capex

–Maintain a strong balance sheet

–Return on Invested Capital > Weighted average cost of capital

28

Injectable Container Solutions

Advanced
Injection
Systems

Prefillable Syringe
Systems

Safety and Administration
Systems

Summary

•Market leader

•Proprietary technology

•Regulatory expertise

•Customer base

•Global footprint

•Partnerships

–Daikyo

–Mexico

•New product pipeline

•Financial position

–Cash flow

–Balance sheet

•People

29

Each and every day,

more than 80 million

West products are used

to enhance the quality of

healthcare around the world.

30

Donald E. Morel, Jr., Ph.D.

Chairman and Chief Executive Officer

William J. Federici

Vice President and Chief Financial Officer

Investor Relations Contact:

Michael A. Anderson

Vice President and Treasurer

mike.anderson@westpharma.com

UBS Global Specialty Pharmaceuticals Conference

June 3, 2009London, UK

NYSE: WST

westpharma.com

All trademarks and registered trademarks are the property of West Pharmaceutical Services, Inc., unless noted otherwise.

31